Abstract：
Ischemia-reperfusion injury (IRI) is directly related to forming reactive oxygen species, endothelial cell injury, increased vascular permeability, and the activation of neutrophils and cytokines. Niosomes are nanocarriers and an essential part of drug delivery systems. We aimed to investigate the effects of myrtenol\'s inhaled and intraperitoneal niosomal form, compared to its simple form, on lung ischemia reperfusion injury (LIRI).
Wistar rats were divided into ten groups. Simple and niosomal forms of myrtenol were inhaled or intraperitoneally injected daily for one week prior to LIRI. We evaluated oxidative stress, apoptotic, and inflammatory indices, nitric oxide, inducible nitric oxide synthase (iNOS), endothelial nitric oxide synthase (eNOS) and histopathological indices.
Pretreatment with simple and niosomal forms of myrtenol significantly inhibited the indices of pulmonary edema, pro-inflammatory cytokines and proteins, oxidant agents, nitric oxide, iNOS, apoptotic proteins, congestion of capillaries, neutrophil infiltration, and bleeding in the alveoli. Furthermore, myrtenol increased anti-inflammatory cytokines, anti-oxidants agents, eNOS, anti-apoptotic proteins and the survival time of animals. The niosomal form of myrtenol showed a more ameliorative effect than its simple form.
The results showed the superior protective effect of the inhalation of myrtenol niosomal form against LIRI compared to its simple form and systemic use.
Wistar rats were divided into ten groups. Simple and niosomal forms of myrtenol were inhaled or intraperitoneally injected daily for one week prior to LIRI. We evaluated oxidative stress, apoptotic, and inflammatory indices, nitric oxide, inducible nitric oxide synthase (iNOS), endothelial nitric oxide synthase (eNOS) and histopathological indices.
Pretreatment with simple and niosomal forms of myrtenol significantly inhibited the indices of pulmonary edema, pro-inflammatory cytokines and proteins, oxidant agents, nitric oxide, iNOS, apoptotic proteins, congestion of capillaries, neutrophil infiltration, and bleeding in the alveoli. Furthermore, myrtenol increased anti-inflammatory cytokines, anti-oxidants agents, eNOS, anti-apoptotic proteins and the survival time of animals. The niosomal form of myrtenol showed a more ameliorative effect than its simple form.
The results showed the superior protective effect of the inhalation of myrtenol niosomal form against LIRI compared to its simple form and systemic use.
摘要：
背景：缺血再灌注损伤（IRI）与形成活性氧直接相关，内皮细胞损伤，血管通透性增加，以及中性粒细胞和细胞因子的激活。脂质体是纳米载体和药物递送系统的重要组成部分。我们的目的是研究吸入和腹腔内注射的莫拉烯醇的作用，与它的简单形式相比，对肺缺血再灌注损伤(LIRI)的影响。
方法：Wistar大鼠分为10组。在LIRI之前，每天吸入或腹膜内注射简单和小脂质体形式的桃金娘酚，持续一周。我们评估了氧化应激，凋亡，和炎症指数，一氧化氮,诱导型一氧化氮合酶（iNOS），内皮型一氧化氮合酶（eNOS）和组织病理学指标。
结果：用简单的和脂质体形式的莫拉烯醇预处理显著抑制肺水肿的指标，促炎细胞因子和蛋白质，氧化剂，一氧化氮,iNOS,凋亡蛋白，毛细血管阻塞，中性粒细胞浸润，肺泡出血.此外，月桂醇增加抗炎细胞因子，抗氧化剂，eNOS,抗凋亡蛋白和动物的存活时间。葡萄烯醇的脂质体形式比其简单形式显示出更大的改善作用。
结论：结果表明，与简单形式和全身使用相比，吸入莫拉烯醇脂质体形式对LIRI的保护作用更好。
方法：Wistar大鼠分为10组。在LIRI之前，每天吸入或腹膜内注射简单和小脂质体形式的桃金娘酚，持续一周。我们评估了氧化应激，凋亡，和炎症指数，一氧化氮,诱导型一氧化氮合酶（iNOS），内皮型一氧化氮合酶（eNOS）和组织病理学指标。
结果：用简单的和脂质体形式的莫拉烯醇预处理显著抑制肺水肿的指标，促炎细胞因子和蛋白质，氧化剂，一氧化氮,iNOS,凋亡蛋白，毛细血管阻塞，中性粒细胞浸润，肺泡出血.此外，月桂醇增加抗炎细胞因子，抗氧化剂，eNOS,抗凋亡蛋白和动物的存活时间。葡萄烯醇的脂质体形式比其简单形式显示出更大的改善作用。
结论：结果表明，与简单形式和全身使用相比，吸入莫拉烯醇脂质体形式对LIRI的保护作用更好。
